Skip to main content
SpringerLink
Log in

Oestrogen Replacement Therapy and Cardiovascular Disease

  • Conference paper
HRT and Osteoporosis

Abstract

Loss of ovarian activity appears to result in an increased risk of cardiovascular disease. Men have higher mortality rates from cardiovascular disease at all ages, but the male to female ratio varies substantially throughout life [1]. The peak ratio occurs in conjunction with the female menopause and declines thereafer. In fact, in one large prospective study in which incident cardiovascular events were closely monitored, male and female rates of cardiovascular disease were indistinguishable by age 70 [2]. In the same study, at any given age women who were postmenopausal had substantially higher rates of cardiovascular disease than premenopausal women [3]. Furthermore, bilateral oophorectomy at a young age has long been known to result in premature development of atherosclerosis and an increased occurrence of its clinical outcomes [4,5].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ross RK, Paganini-Hill A. Estrogen replacement therapy and coronary heart disease. Sem Reprod Endocrinol 1983; 1:19–25.

    Article  Google Scholar 

  2. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and the risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976; 85:447–52.

    PubMed  CAS  Google Scholar 

  3. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease: the Framingham study. Ann Intern Med 1978; 89:157–61.

    PubMed  CAS  Google Scholar 

  4. Robinson RW, Higano N, Cohen WD. Increased incidence of coronary heart disease in women castrated prior to the menopause. Arch Intern Med 1959; 104:908–13.

    Article  PubMed  CAS  Google Scholar 

  5. Parris HM, Carr CA, Hall DG, King TM. Time interval from castration in premenopausal women to development of excessive coronary atherosclerosis. Am J Obstet Gynecol 1967; 99:155–67.

    Google Scholar 

  6. Healthy People: The Surgeon General’s Report on Health Promotion and Disease Prevention 1979. DHEW (PHS) Publication No. 79–55071, Washington, DC, US Government Printing Office, 1979.

    Google Scholar 

  7. Kennedy LD, Baum C, Forbes MD. Non-contraceptive estrogens and progestins: use patterns over time. Obstet Gynecol 1985; 65:441–6.

    PubMed  CAS  Google Scholar 

  8. Pick R, Stamler J, Rodbard S, Katz LN. The inhibition of coronary atherosclerosis by estrogens in cholesterol-fed chicks. Circulation 1952; 6:276–80.

    PubMed  CAS  Google Scholar 

  9. Adams MR, Clarkson TB, Koritnik DR, Nash HA. Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques. Fertil Steril 1987; 47:1010–18.

    PubMed  CAS  Google Scholar 

  10. Ludden JB, Bruger M, Wright IS. Experimental atherosclerosis — effect of testosterone proprionate and estradiol diproprionate on experimental atherosclerosis. Arch Pathol 1952; 33:58–62.

    Google Scholar 

  11. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981; i:858–60.

    Article  Google Scholar 

  12. Rosenberg L, Armstrong B, Jick H. Myocardial infarction and estrogen therapy in postmenopausal women. N Engl J Med 1976; 294:1256–9.

    Article  PubMed  CAS  Google Scholar 

  13. Pfeffer RI, Whipple GH, Kurosaki TT, Chapman JM. Coronary risk and estrogen use in postmenopausal women. Am J Epidemiol 1978; 107:479–87.

    PubMed  CAS  Google Scholar 

  14. Bain C. Willett W, Hennekens CH, Rosenr B, Belanger C, Speizer FE. Use of postmenopausal hormones and risk of myocardial infarction. Circulation 1981; 64:42–5.

    Article  PubMed  CAS  Google Scholar 

  15. Jick H, Dinan B, Rothman KJ. Noncontraceptive estrogens and non-fatal myocardial infarction. JAMA 1978; 239:1407–8.

    Article  PubMed  CAS  Google Scholar 

  16. Rosenberg L, Slone D. Shapiro S, Kaufman D, Stolley PD, Miettinen OS. Noncontraceptive estrogens and myocardial infarction in young women. JAMA 1980; 244:339–42.

    Article  PubMed  CAS  Google Scholar 

  17. Adam S, Williams V, Vessey MP. Cardiovascular disease and hormone replacement treatment: a pilot case-control study. Br Med J 1981; 282:1277–8.

    Article  CAS  Google Scholar 

  18. Szklo M, Tonascia J. Gordis L, Bloom I. Estrogen use and myocardial infarction risk: a case-control study. Prev Med 1984; 13:510–16.

    Article  PubMed  CAS  Google Scholar 

  19. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners’ Oral Contraception Study. Br Med J 1989; 298:165–8.

    Article  CAS  Google Scholar 

  20. Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J. Epidemiol Community Health 1989; 43:173–8

    Article  PubMed  CAS  Google Scholar 

  21. Hammond CB, Jelovsek Fr, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol 1979; 133:525–36.

    PubMed  CAS  Google Scholar 

  22. Burch JC, Byrd BF, Vaughn WK. The effects of long-term estrogen on hysterectomized women. Am J Obstet Gynecol 1974; 118:778–82.

    PubMed  CAS  Google Scholar 

  23. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985; 313:1104–49

    Article  Google Scholar 

  24. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham study. N Engl J Med 1985; 313:1038–43.

    Article  PubMed  CAS  Google Scholar 

  25. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988; 159:312–17.

    PubMed  CAS  Google Scholar 

  26. Petitti DB, Perlman JA, Sidney S. Postmenopausal estrogen use and heart disease (Letter). N Engl J Med 1986; 315:131.

    Article  Google Scholar 

  27. Bush TL, Barrett-Conner E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program follow-up study, circulation 1987; 75:1102–9.

    Google Scholar 

  28. Criqui MH, Suarez L, Barrett-Conner E, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality: results from a prospective study in a defined homogeneous community. Am J Epidemiol 1988; 128:606–14.

    PubMed  CAS  Google Scholar 

  29. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94:620–34.

    Article  PubMed  CAS  Google Scholar 

  30. Petitti DB, Wingerd J, Pellegrin F, Ramchuran S. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens and other factors. JAMA 1979; 242:1150–4.

    Article  PubMed  CAS  Google Scholar 

  31. Postmenopausal estrogen use and heart disease (Letters). N Engl J Med 1987; 315:1274.

    Google Scholar 

  32. Eaker ED, Castelli WP. Differential risk for coronary heart disease among women in the Framingham Study. In: Proceedings of the workshop on coronary heart disease in women. Bethesda, MD, National Institutes of Health (NIH Administrative RP no., 1987).

    Google Scholar 

  33. Ross RK. Progestogens and the cardiovascular system. Int Proc J 1989; 1:218–34.

    Google Scholar 

  34. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy (in review).

    Google Scholar 

  35. Jenson J, Christiansen C, Rodbro P. Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N Engl J Med 1985; 313:973–5.

    Article  Google Scholar 

  36. Bush JL, Miller VT. Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins. In: Mishell DR, ed. Menopause, physiology and pharmacology. Chicago, Yearbook Medical Publishers, 1987; 187–208.

    Google Scholar 

  37. Pitt B, Shea MJ, Romson JL, Lucchesi BR. Prostaglandins and prostaglandin inhibitors in ischemic heart disease. Ann Intern Med 1983; 99:83–92.

    PubMed  CAS  Google Scholar 

  38. Ylikorkala O, Puolakka J, Viinikka, L. Vasoconstrictory thromboxane A2 and vasodilatory prostacyclin in climacteric women: effect of oestrogen-progestogen therapy. Maturitas 1984; 5:201–5.

    Article  PubMed  CAS  Google Scholar 

  39. Mileikowsky GN, Nadler JL, Huey F, Francis R, Roy S. Evidence that smoking alters prostacyclin formation and platelet aggregation in women who use oral contraceptives. Am J Obstet Gynecol 1988; 159:1547–52.

    PubMed  CAS  Google Scholar 

  40. Hirvonenu E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981; 304–560–3.

    Article  Google Scholar 

  41. Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985; 151:746–50.

    PubMed  CAS  Google Scholar 

  42. Hirvonen E, Lipasti A, Malkonen M et al. Clinical and lipid metabolic effects of unopposed oestrogen and two oestrogen-progestogen regimens in post-menopausal women. Maturitas 1987; 9:69–79.

    Article  PubMed  CAS  Google Scholar 

  43. Sherwin BB, Gelfand MM. A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstet Gynecol 1989; 73:759–66.

    PubMed  CAS  Google Scholar 

  44. Sonnendecker EWW, Polakow S, Benade AJS, Simchowitz E. Serum lipoprotein effects of conjugated estrogen and a sequential conjugated estrogen-medrogesterone regimen in hysterectomized postmenopausal women. Am J Obstet Gynecol 1989; 160:1128–34.

    PubMed  CAS  Google Scholar 

  45. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980’s. JAMA 1989; 261:2095–100.

    Article  PubMed  CAS  Google Scholar 

  46. von Kaulla E, Droegemueller W, von Kaulla KN. Conjugated estrogens and hypercoagulability. Am J Obstet Gynecol 1974; 122:688–92.

    Google Scholar 

  47. Chetkowski RJ, Meldrum DR, Steingold KA et al. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314:1615–20.

    Article  PubMed  CAS  Google Scholar 

  48. Sharf M, Oettinger M, Lanir A, Kahana L, Yeshurun D. Lipid and lipoprotein levels following pure estradiol implantation in postmenopausal women. Gynecol Obstet Invest 1985; 19:207–12.

    Article  PubMed  CAS  Google Scholar 

  49. Jensen J, Riis BJ, Strom V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 1987; 156:66–71.

    PubMed  CAS  Google Scholar 

  50. Notelovitz M, Johnston M, Smith S, Kitchens C. Metabolic and hormonal effects of 25-mg and 50-mg 17ß-estradiol implants in surgically menopausal women. Obstet Gynecol 1987; 70:749–54.

    PubMed  CAS  Google Scholar 

  51. Stanclzdyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA. A randomized comparison of normal estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988; 159:1540–6.

    Google Scholar 

  52. Henderson BE, Ross RK, Lobo RA et al. Re-evaluating the role of progestogen therapy after the menopause. Fertil Steril 1988; 49:9S–15S.

    PubMed  CAS  Google Scholar 

  53. Ross RK, Pike MC, Henderson BE, Mack TM, Lobo RA. Stroke prevention and oestrogen replacement therapy. (Letter) Lancet 1989; i:505.

    Article  Google Scholar 

  54. Bergkvist O, Adami HO, Persson I, Bergstrom R, Kruseno UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemol 1989; 130:221–8.

    CAS  Google Scholar 

Download references

Authors
  1. R. K. Ross
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. C. Pike
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. M. Mack
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. E. Henderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Clarendon Wing, Leeds General Infirmary, Leeds, LS1 3EX, UK

    James O. Drife MD, FRCS Ed, FRCOG (Professor of Obstetrics and Gynaecology) (Professor of Obstetrics and Gynaecology)

  2. King’s College Hospital, London, SE5 9RS, UK

    John W. W. Studd MD, BS, FRCOG (Consultant Obstetrician and Gynaecologist, Director) (Consultant Obstetrician and Gynaecologist, Director)

  3. The Menopause Clinic, Dulwich Hospital, East Dulwich Grove, London, SE22 8PT, UK

    John W. W. Studd MD, BS, FRCOG (Consultant Obstetrician and Gynaecologist, Director) (Consultant Obstetrician and Gynaecologist, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag London Limited

About this paper

Cite this paper

Ross, R.K., Pike, M.C., Mack, T.M., Henderson, B.E. (1990). Oestrogen Replacement Therapy and Cardiovascular Disease. In: Drife, J.O., Studd, J.W.W. (eds) HRT and Osteoporosis. Springer, London. https://doi.org/10.1007/978-1-4471-1799-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-1799-5_17

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-1801-5

  • Online ISBN: 978-1-4471-1799-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation